At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 149 enrolled
Drug / intervention
TJ003234 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
In Brief
A Phase 3 clinical trial evaluating TJ003234 and Placebo for Coronavirus Disease 2019 COVID-19. Completed, enrolled 149 participants across 14 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and to assess the effect of TJ003234 on the levels of cytokines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Disease 2019 COVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartApr 2020
Primary CompletionFeb 2022
TodayJul 2026
First PostedApr 10, 2020
Enrollment StartApr 11, 2020
Primary CompletionFeb 7, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.2 years ago
Interventions
TJ003234drug
patients receive a single infusion
Placebodrug
patients receive a single infusion